Excellergy

Excellergy is a biotechnology company developing a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases and help improve patient quality of life. By leveraging clinically validated Immunoglobulin E (IgE) biology with novel ECRI pharmacology, Excellergy is advancing beyond traditional anti-IgE approaches to directly target the source of allergic signaling—IgE bound to the effector cell. The company was founded by leaders in the field of IgE biology and the molecular pharmacology of anti-IgE therapeutics.